Onglyza Lawsuit Alleging Wrongful Death From Heart Failure Filed in Illinois, Bernstein Liebhard LLP Reports

November 9, 2015 - A new Onglyza lawsuit (www.onglyzalawsuit2015.com) has been filed in Illinois' Cook County Circuit Court by the daughter of a woman who died from heart failure allegedly related to her use of the Type 2 diabetes medication. According to the October 29th filing, the Decedent was prescribed Onglyza in 2010 and was diagnosed with heart failure the following year. She was hospitalized twice before she died in October 2013 from complications related to her heart condition. (Case No. 2015-L-010969)

"The filing of this claim comes as the FDA considers adding new information to the Onglyza label regarding a possible association with an increased risk of heart failure. Our Firm has heard from a number of Onglyza patients who were allegedly harmed by this medication, and we will be monitoring this matter closely," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free Onglyza lawsuit reviews to individuals who were diagnosed with heart failure while being treated with this Type 2 diabetes medication.

Onglyza and Heart Failure
Onglyza (saxagliptin) is a DPP-4 inhibitor indicated to improve glycemic control in individuals with Type 2 diabetes. The medication was approved by the U.S. Food & Drug Administration (FDA) in July 2009, and brought in more than $700 million in sales in 2012. Onglyza was developed jointly by AstraZeneca and Bristol-Myers Squibb, and is now marketed solely by AstraZeneca.

In 2014, the FDA announced that it was reviewing a possible association between Onglyza and heart failure, after a study published in the New England Journal of Medicine reported that exposure to saxagliptin appeared to be associated with a 27% increase in hospitalizations for heart failure, as well as a higher risk of all-cause mortality. In April, the agency convened a meeting of its Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) to further review data from study, at which time the Committee voted 14-to-1 to recommend that the Onglyza label be revised to include information about a potential risk of heart failure. While the FDA is not required to follow the recommendations of its advisory panels, it usually does so.

Compensation may be available to Onglyza patients who were diagnosed with heart failure while using this Type 2 diabetes medication. To learn more about filing an Onglyza lawsuit, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.onglyzalawsuit2015.com/
https://plus.google.com/115936073311125306742?rel=author